Paul Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul Zhang has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Alexander C. Huang
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
24 shared publications - Amanda Cervini
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
24 shared publications - Amy Marshall
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
24 shared publications - Andrea Brennan
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
24 shared publications - Carl H. June
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
24 shared publications - E. John Wherry
Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, USA
24 shared publications
Latest Publications
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- p. OF1-OF11
SGLT2-Mediated Glucose Uptake Defines Early Metabolic Reprogramming in Lung Adenocarcinoma
The metabolic reprogramming taking place during early lung adenocarcinoma progression remains poorly understood. Although early-stage lung adenocarcinoma frequently demonstrates low 2[18F]fluoro-2-deoxy-D-glucose (18FDG) uptake on positron emission tomography (PET), it is unclear whether this reflects metabolic quiescence or alternative glucose utilization pathways. We hypothesized that early lesions are metabolically active but preferentially utilize sodium–glucose cotransporter 2 (SGLT2), a noncanonical glucose transporter with low 18FDG affinity. This study investigates metabolic activity in early-stage lung adenocarcinoma and glucose transporter expression patterns across the adenocarcinoma spectrum. Lactate dehydrogenase (LDH), SGLT2, and glucose transporter-1 (GLUT1) expression was evaluated by immunohistochemistry in human lung cancers and compared with normal lung (NL) and benign inflammation. Expression levels were correlated with structural and radiologic features, including tumor size, invasion, histology, radiographic features, and PET avidity. Glycolysis was elevated in premalignant and early lung adenocarcinoma, as indicated by LDH expression. SGLT2 was highly expressed in preinvasive and minimally invasive lung adenocarcinoma compared with NL and invasive tumors. Conversely, GLUT1 was upregulated in invasive, high-grade tumors. Radiographically, SGLT2 expression was associated with subsolid nodules and low PET avidity, whereas GLUT1 expression was higher in nodules with a solid component and high 18FDG avidity. Notably, SGLT2 was not elevated in inflammatory lesions compared with NL, unlike GLUT1, which was frequently upregulated in inflammation. Early lung adenocarcinoma lesions exhibit aerobic glycolysis despite low 18FDG avidity and preferentially utilize SGLT2-mediated glucose uptake. These findings highlight a distinct metabolic profile in early lung adenocarcinoma and underscore the need for alternative imaging modalities to enhance the detection of early lesions. Prevention Relevance: This study identifies a distinct metabolic phenotype in premalignant and early-stage lung adenocarcinoma characterized by preferential SGLT2 expression and low PET avidity. These findings support the investigation of SGLT2-targeted imaging strategies to improve the detection of early lung adenocarcinoma when curative intervention is most effective.
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- p. OF1-OF11
SGLT2-Mediated Glucose Uptake Defines Early Metabolic Reprogramming in Lung Adenocarcinoma
The metabolic reprogramming taking place during early lung adenocarcinoma progression remains poorly understood. Although early-stage lung adenocarcinoma frequently demonstrates low 2[18F]fluoro-2-deoxy-D-glucose (18FDG) uptake on positron emission tomography (PET), it is unclear whether this reflects metabolic quiescence or alternative glucose utilization pathways. We hypothesized that early lesions are metabolically active but preferentially utilize sodium–glucose cotransporter 2 (SGLT2), a noncanonical glucose transporter with low 18FDG affinity. This study investigates metabolic activity in early-stage lung adenocarcinoma and glucose transporter expression patterns across the adenocarcinoma spectrum. Lactate dehydrogenase (LDH), SGLT2, and glucose transporter-1 (GLUT1) expression was evaluated by immunohistochemistry in human lung cancers and compared with normal lung (NL) and benign inflammation. Expression levels were correlated with structural and radiologic features, including tumor size, invasion, histology, radiographic features, and PET avidity. Glycolysis was elevated in premalignant and early lung adenocarcinoma, as indicated by LDH expression. SGLT2 was highly expressed in preinvasive and minimally invasive lung adenocarcinoma compared with NL and invasive tumors. Conversely, GLUT1 was upregulated in invasive, high-grade tumors. Radiographically, SGLT2 expression was associated with subsolid nodules and low PET avidity, whereas GLUT1 expression was higher in nodules with a solid component and high 18FDG avidity. Notably, SGLT2 was not elevated in inflammatory lesions compared with NL, unlike GLUT1, which was frequently upregulated in inflammation. Early lung adenocarcinoma lesions exhibit aerobic glycolysis despite low 18FDG avidity and preferentially utilize SGLT2-mediated glucose uptake. These findings highlight a distinct metabolic profile in early lung adenocarcinoma and underscore the need for alternative imaging modalities to enhance the detection of early lesions. Prevention Relevance: This study identifies a distinct metabolic phenotype in premalignant and early-stage lung adenocarcinoma characterized by preferential SGLT2 expression and low PET avidity. These findings support the investigation of SGLT2-targeted imaging strategies to improve the detection of early lung adenocarcinoma when curative intervention is most effective.
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
TABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
TABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
MRNA signals corresponding to CAR T cells in peripheral blood
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
MRNA signals corresponding to CAR T cells in peripheral blood
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had preinfusion and postinfusion tumor tissue available for analysis; postinfusion tumor tissue demonstrated an increase in cytoxic CD8+ cells in all 3 subjects.
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had preinfusion and postinfusion tumor tissue available for analysis; postinfusion tumor tissue demonstrated an increase in cytoxic CD8+ cells in all 3 subjects.
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
MRNA signals corresponding to CAR T cells in peripheral blood
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
MRNA signals corresponding to CAR T cells in peripheral blood
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of paired tumor tissue
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of paired tumor tissue
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
TABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of paired tumor tissue
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of paired tumor tissue
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Supplementary Figure 2: Representative immunohistochemical staining for Subject 27 with metastatic triple-negative breast cancer; lymph node biopsy. Panel A shows CD8 staining prior to infusion and Panel B shows CD8 staining at the time of post-infusion biopsy.
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Supplementary Figure 2: Representative immunohistochemical staining for Subject 27 with metastatic triple-negative breast cancer; lymph node biopsy. Panel A shows CD8 staining prior to infusion and Panel B shows CD8 staining at the time of post-infusion biopsy.
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Supplementary Figure 1.: Representative immunohistochemical staining for Subject 74 with metastatic melanoma; lymph node biopsy. Panel A: pS6 staining prior to infusion; Panel B: pS6 staining at post-infusion biopsy; Panel C: Ki-67 staining prior to infusion; Panel D: Ki-67 staining at post-infusion biopsy.
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Supplementary Figure 1.: Representative immunohistochemical staining for Subject 74 with metastatic melanoma; lymph node biopsy. Panel A: pS6 staining prior to infusion; Panel B: pS6 staining at post-infusion biopsy; Panel C: Ki-67 staining prior to infusion; Panel D: Ki-67 staining at post-infusion biopsy.
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had preinfusion and postinfusion tumor tissue available for analysis; postinfusion tumor tissue demonstrated an increase in cytoxic CD8+ cells in all 3 subjects.
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had preinfusion and postinfusion tumor tissue available for analysis; postinfusion tumor tissue demonstrated an increase in cytoxic CD8+ cells in all 3 subjects.